Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00479583 · ClinicalTrials.gov registry record · Phase 1
Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00479583 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 25 participants.
The verdict
NCT00479583, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the highest dose of BMS-690514 that can be safely given in combination with the chemotherapeutic regimens (FOLFIRI and FOLFOX) to patients with advanced cancer
Interventions
- DRUG BMS-690514 / FOLFIRI
- DRUG BMS-690514 / FOLFOX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2007-09 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00479583
The ClinicalTrials.gov registry entry for NCT00479583 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-690514 / FOLFIRI is the first listed.
NCT00479583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00479583 about?
NCT00479583 is a clinical study titled "Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX". The purpose of this research study is to determine the highest dose of BMS-690514 that can be safely given in combination with the chemotherapeutic regimens (FOLFIRI and FOLFOX) to patients with advanced cancer
What is the current status of trial NCT00479583?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2007-09. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00479583?
The interventions under investigation include: BMS-690514 / FOLFIRI (DRUG), BMS-690514 / FOLFOX (DRUG).
Who is sponsoring clinical trial NCT00479583?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.